Joseph A. Sparano, MD, on HR+, HER2– Breast Cancer: Individualizing Prognosis and Predicting Treatment Success
2020 San Antonio Breast Cancer Symposium
Joseph A. Sparano, MD, of the Montefiore Medical Center and Albert Einstein College of Medicine, discusses the development and validation of a tool that integrates the 21-gene recurrence score and clinicopathologic features to individualize prognosis for distant recurrence and predict chemotherapy benefit in patients with early breast cancer with greater precision (Abstract GS4-10).
Joyce V. Lee, PhD, of the University of California, San Francisco, discusses data that suggest the MYC oncogene may indicate whether a patient with triple-negative breast cancer will respond to immunotherapy. Dr. Lee’s study is the first to describe MYC downregulation of MHC-I and to demonstrate translatable approaches that may overcome immune evasion (Abstract GS1-08).
Roisin M. Connolly, MD, of University College Cork, discusses phase III results from the E2112 trial, which showed exemestane plus entinostat did not improve survival in aromatase inhibitor–resistant advanced HR-positive, HER2-negative breast cancer (Abstract GS4-02).
Lee S. Schwartzberg, MD, of the West Cancer Center, discusses phase III results from the CONTESSA study, which showed that an all-oral regimen of tesetaxel plus a reduced dose of capecitabine significantly improved progression-free survival compared with capecitabine alone in patients with HER2-negative, hormone receptor–positive metastatic breast cancer previously treated with a taxane (Abstract GS4-01).
Editor's note: On March 22, 2021, Odonate Therapeutics announced it was discontinuing the development of tesetaxel and will close the company's operations. Read more here.
Patricia A. Ganz, MD, of the University of California, Los Angeles, discusses study findings that showed mindfulness meditation and survivorship education may effectively reduce depression and related symptoms such as fatigue and sleep disturbance, which pose serious threats to younger women’s health and well-being after being treated for cancer (Abstract GS2-10).
Sara A. Hurvitz, MD, of the David Geffen School of Medicine at UCLA, discusses phase III data from the ASCENT study of the antibody-drug conjugate sacituzumab govitecan vs chemotherapy in patients with previously treated metastatic triple-negative breast cancer (Abstract GS3-06).